| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15941009 | IVR | 165 mg/kg | 165 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations |
| IVR | 55 mg/kg | 55 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| PMID:25554385 | IVR | 0.105 mg/kg/day | 0.105 mg/kg/day | Affects survival of live fetus | Reproductive endocrine-mediated perturbations |
| IVR | 0.105 mg/kg/day | 0.105 mg/kg/day | Changes in mammary gland morphology | Reproductive endocrine-mediated perturbations | |
| PMID:27535158 | IVR | 100 mg/kg/day | 100 mg/kg/day | Lead to obesity | Metabolic endocrine-mediated perturbations |
| PMID:27581495 | IVTH | 0.00000001 M | 0.00000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| PMID:28181406 | IVR | 500 mg/kg/day | 500 mg/kg/day | Prostate hyperplasia | Reproductive endocrine-mediated perturbations |
| IVR | 500 mg/kg/day | 500 mg/kg/day | Cancer phenotype | Endocrine-mediated cancer |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.